Archive | Melanoma In The News

Adding Coxsackievirus to Ipilimumab Displays Durable Antitumor Activity in Advanced Melanoma

Adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to ipilimumab (Yervoy) yielded an overall response rate (ORR) of 50% and was well-tolerated in immunotherapy-naïve and pretreated patients with advanced melanoma.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Combined immunotherapy shows early promise in advanced melanoma

Patients with advanced melanoma derived benefit from a combination of ipilimumab and Coxsackievirus A21, according to a phase 1b clinical trial presented at the American Association for Cancer Research Annual Meeting.

Read the full story

Posted in Melanoma In The News, Information

Early-stage Eye Melanoma Trial Tests Less-invasive Treatment Approach

Patients with ocular melanoma, a type of melanoma that develops in the eye, have a potentially new and groundbreaking treatment option being assessed in a Phase 1 clinical trial.

Read the full story

Posted in Melanoma In The News, Information

Updated Melanoma Survival Data for Opdivo + Yervoy Presented at AACR 2017

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) —two immunotherapies developed by Bristol-Myers Squibb —demonstrated improved survival compared to nivolumab alonein patients with previously untreated advanced melanoma in a recent phase III study.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories